Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9767723 | 0.92 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2NT5EKMT2A | |
| SCHEMBL611657 | 0.92 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2NT5EKMT2A | |
| SCHEMBL10939703 | 0.92 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2NT5EKMT2A | |
| SCHEMBL3035517 | 0.88 | HDAC8 (0.68) | HDAC8HDAC6HDAC2NPC1RAB9A | |
| SCHEMBL202512 | 0.88 | HDAC1 (0.65) | HDAC8HDAC6HDAC2HDAC1HDAC3 | |
| SCHEMBL4168784 | 0.87 | KMT2A (0.65) | NPC1RAB9ASMN1; SMN2NT5EKMT2A | |
| SCHEMBL10373278 | 0.87 | NPC1 (0.65) | HDAC8NPC1RAB9ASMN1; SMN2NT5E | |
| SCHEMBL3028810 | 0.87 | HDAC8 (0.67) | HDAC8HDAC6HDAC2NPC1RAB9A | |
| SCHEMBL6710662 | 0.85 | MITF (0.68) | NPC1RAB9ASMN1; SMN2NT5EKMT2A | |
| SCHEMBL6556039 | 0.85 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2NT5EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | BAIOCCHI ROBERT A (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143314-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | ARNO THERAPEUTICS, INC (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011103563-A1 | METHODS AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE GROWTH OF MALIGNANT MAST CELLS | ARNO THERAPEUTICS, INC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-28 | — | — | US | disclosed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC8 14/4885HDAC6 13/4885HDAC2 5/4885 |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | HDAC1, HDAC9, HDAC3 | HDAC8 9/4885HDAC6 13/4885HDAC2 4/4885 |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | HDAC1, HDAC4, HDAC2 | HDAC8 9/4885HDAC6 10/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.